Results 51 to 60 of about 961,635 (194)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency

open access: yesMolecular Genetics and Metabolism Reports, 2023
Background: Creatine transporter deficiency (CTD) is a rare X-linked disorder of creatine transport caused by pathogenic variants in SLC6A8 (Xq28). The disorder is marked by developmental delay, especially speech delay.
Samar Rahhal   +14 more
doaj   +1 more source

The Concept of Folic Acid in Health and Disease

open access: yesMolecules, 2021
Folates have a pterine core structure and high metabolic activity due to their ability to accept electrons and react with O-, S-, N-, C-bounds.
Yulia Shulpekova   +9 more
doaj   +1 more source

Ammonium alters creatine transport and synthesis in a 3D culture of developing brain cells, resulting in secondary cerebral creatine deficiency

open access: yesEuropean Journal of Neuroscience, 2008
AbstractHyperammonemic disorders in pediatric patients lead to poorly understood irreversible effects on the developing brain that may be life‐threatening. We showed previously that some of these NH4+‐induced irreversible effects might be due to impairment of axonal growth that can be protected under ammonium exposure by creatine co‐treatment.
O. Braissant   +6 more
semanticscholar   +6 more sources

A novel mouse model of creatine transporter deficiency [v1; ref status: indexed, http://f1000r.es/4f8]

open access: yesF1000Research, 2014
Mutations in the creatine (Cr) transporter (CrT) gene lead to cerebral creatine deficiency syndrome-1 (CCDS1), an X-linked metabolic disorder characterized by cerebral Cr deficiency causing intellectual disability, seizures, movement  and behavioral ...
Laura Baroncelli   +9 more
doaj   +1 more source

A novel mouse model of creatine transporter deficiency [v2; ref status: indexed, http://f1000r.es/4zb]

open access: yesF1000Research, 2015
Mutations in the creatine (Cr) transporter (CrT) gene lead to cerebral creatine deficiency syndrome-1 (CCDS1), an X-linked metabolic disorder characterized by cerebral Cr deficiency causing intellectual disability, seizures, movement  and behavioral ...
Laura Baroncelli   +10 more
doaj   +1 more source

X‐linked creatine transporter deficiency: clinical aspects and pathophysiology

open access: yes, 2014
Creatine transporter deficiency was discovered in 2001 as an X-linked cause of intellectual disability characterized by cerebral creatine deficiency. This review describes the current knowledge regarding creatine metabolism, the creatine transporter and ...
Salomons, GS   +5 more
core   +1 more source

Homoarginine and creatine deficiency do not exacerbate murine ischaemic heart failure [PDF]

open access: yes, 2022
Aims Low levels of homoarginine and creatine are associated with heart failure severity in humans, but it is unclear to what extent they contribute to pathophysiology. Both are synthesized via L-arginine:glycine amidinotransferase (AGAT), such that AGAT−/
Debra J. McAndrew   +13 more
core   +1 more source

Autism spectrum disorder in patients with inherited metabolic disorders-a large sample from a tertiary center

open access: yesThe Turkish Journal of Pediatrics, 2021
Background. There is increased awareness regarding the co-occurrence of autism spectrum disorder (ASD) and inherited metabolic disorders (IMD), and this is crucial for the management of both diagnoses in clinical practice.
Tuba Çelen Yoldaş   +4 more
doaj   +1 more source

Progressive intestinal, neurological and psychiatric problems in two adult males with cerebral creatine deficiency caused by an SLC6A8 mutation [PDF]

open access: yesClinical Genetics, 2005
Contains fulltext : 47949.pdf (Publisher’s version ) (Open Access)
T. Kleefstra   +6 more
semanticscholar   +5 more sources

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy